CAR T-Cell Therapy Surpasses 90% Complete Remission Rate in Pediatric ALL
Andrew J. Roth
Published: Friday, Apr 24, 2015
Michael Jensen, MD
The chimeric antigen receptor (CAR) T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL), according to results from a phase I trial presented at the 2015 AACR Annual Meeting.
... to read the full story